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ABSTRACT
Inhibition of neurohumoural pathways such as the renin
angiotensin aldosterone and sympathetic nervous
systems is central to the understanding and treatment of
heart failure (HF). Conversely, until recently, potentially
beneficial augmentation of neurohumoural systems such
as the natriuretic peptides has had limited therapeutic
success. Administration of synthetic natriuretic peptides
has not improved outcomes in acute HF but modulation
of the natriuretic system through inhibition of the
enzyme that degrades natriuretic (and other vasoactive)
peptides, neprilysin, has proven to be successful. After
initial failures with neprilysin inhibition alone or dual
neprilysin-angiotensin converting enzyme (ACE)
inhibition, the Prospective comparison of angiotensin
receptor neprilysin inhibitor (ARNI) with ACEI to
Determine Impact on Global Mortality and morbidity in
Heart Failure trial (PARADIGM-HF) trial demonstrated
that morbidity and mortality can be improved with the
angiotensin receptor blocker neprilysin inhibitor
sacubitril/valsartan (formerly LCZ696). In comparison to
the ACE inhibitor enalapril, sacubitril/valsartan reduced
the occurrence of the primary end point (cardiovascular
death or hospitalisation for HF) by 20% with a 16%
reduction in all-cause mortality. These findings suggest
that sacubitril/valsartan should replace an ACE inhibitor
or angiotensin receptor blocker as the foundation of
treatment of symptomatic patients (NYHA II–IV) with HF
and a reduced ejection fraction. This review will explore
the background to neprilysin inhibition in HF, the results
of the PARADIGM-HF trial and offer guidance on how to
use sacubitril/valsartan in clinical practice.
The renin angiotensin aldosterone system (RAAS)
system is at the core of the pathophysiology of
heart failure (HF) and its modulation is central to
altering the disease process in HF with reduced
ejection fraction (HF-REF). Successive randomised
controlled trials have demonstrated that blockade
of RAAS improves morbidity and mortality in
patients with HF-REF.1–3 The prognosis of
HF-REF has been improved as a consequence,
although it remains poor4 as it remains a complex
syndrome involving a multitude of neurohormonal
pathways. Therefore, further therapies to improve
outcomes in these patients are needed.
THE NATRIURETIC PEPTIDE SYSTEM
The natriuretic peptide system counter regulates
the detrimental effects of the upregulation of RAAS
that occurs in HF-REF, inhibits secretion of argin-
ine vasopressin and modulates the autonomic
nervous system in ways that are likely to be benefi-
cial in this syndrome.5 Sodium and water retention
and vasoconstriction caused by activation of RAAS
and the sympathetic nervous system, and the action
of vasopressin, lead to increased ventricular preload
and afterload and elevated wall stress which in turn
lead to production of pre-pro B-type natriuretic
peptide (BNP) which is cleaved to BNP and
N-terminal proBNP (NT-proBNP). The release of
natriuretic peptides may also be determined by the
levels of other neurohormones such as angiotensin
II and endothelin.6 The peptide BNP acts to
promote natriuresis and vasodilation (NT-proBNP is
physiologically inactive). Atrial stretch leads to the
production of pre-proatrial or A-type natriuretic
peptide and ultimately atrial natriuretic peptide
(ANP) which has similar biological properties to
BNP.5 Urodilatin (which is structurally related to
ANP), is derived from the same precursor in the
kidneys.7 C-type natriuretic peptide (CNP) is
released from endothelial cells and acts in a para-
crine fashion but is only found in low concentra-
tions in circulating blood.5 Two strategies have been
employed to try and improve outcomes in HF-REF
via modulation of this pathway. The first is the
administration of exogenous natriuretic peptides.
Nesiritide, a recombinant human BNP, initially
showed promising beneficial effects on haemo-
dynamics and natriuresis in patients with HF-REF.8
However, in a large-scale randomised controlled
trial, nesiritide failed to improve outcomes (though
it did improve dyspnoea).9 Although carperitide
(recombinant ANP) is used as a treatment for acute
HF in Japan, there is no robust evidence supporting
this practice.10 The second strategy is to inhibit the
breakdown of natriuretic peptides. ANP, BNP, CNP
and urodilatin are cleaved and inactivated by a mem-
brane bound endopeptidase, neprilysin (as well as
insulin degrading enzyme). Neprilysin is found in a
number of tissues but in especially high concentra-
tions in the kidney. Natriuretic peptides are also
cleared via the natriuretic peptide clearance receptor
(NPRC and NPRC3).
INITIAL NEPRILYSIN INHIBITORS
Initial attempts at inhibiting neprilysin using an
oral (racecodotril11) and intravenous (candoxatri-
lat12) formulation were successful in promoting
natriuresis and increasing urinary excretion of ANP.
A further neprilysin inhibitor (ecadotril) had
similar effects.13 However, a study of chronic use
of the oral prodrug candoxatril showed that the
initial reduction in blood pressure was not sus-
tained and therefore development was stopped.14
This might be explained by the finding that neprily-
sin also breaks down angiotensin II.15–17 Therefore
inhibiting neprilysin alone, while raising natriuretic
peptides levels, also increases angiotensin II levels
(and other substrates for neprilysin such as
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endothelin, vasopressin, bradykinin, etc) potentially counteract-
ing the actions of the former peptides.
DUAL NEPRILYSIN AND ACE INHIBITION
The solution to the problem of lone neprilysin inhibition
appeared to be dual blockade of RAAS and the natriuretic
peptide system (figure 1). As ACE inhibitors are known to
improve outcomes it seemed logical to combine an ACE inhibitor
with a neprilysin inhibitor. The combined ACE and neprilysin
inhibitor omapatrilat was studied in a large randomised con-
trolled trial against enalapril 10 mg twice daily in the
Omapatrilat Versus Enalapril Randomized Trial of Utility in
Reducing Events (OVERTURE) trial.18 The primary end point,
death from any cause or HF hospitalisations were not reduced by
omapatrilat. Although other secondary end points suggested a
benefit with omapatrilat (death from any cause or cardiovascular
(CV) hospitalisation was 9% lower in the omapatrilat group) the
rate of angio-oedema was much higher in the omapatrilat group.
Both ACE and neprilysin break down bradykinin and omapatrilat
also inhibits aminopeptidase P which also catabolises bradykinin.
Therefore, unintended excessive potentiation of bradykinin and
resultant high rates of serious angio-oedema led to the discon-
tinuation of the clinical development of this drug.
ANGIOTENSIN RECEPTOR BLOCKER NEPRILYSIN
INHIBITORS
Combining an angiotensin receptor blocker (ARB) and a nepri-
lysin inhibitor was the logical next step and potential solution to
the problem encountered with omapatrilat. The angiotensin
receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (for-
merly known as LCZ696) was designed with the aim of inhibit-
ing neprilysin while blocking the adverse effects of RAAS and
reducing bradykinin potentiation.19–21 The drug LCZ696 is
made of the ARB valsartan and neprilysin inhibitor prodrug
sacubitril. As the active metabolite of sacubitril, sacubitrilat
(LBQ657), does not inhibit aminopeptidase P, the risk of
angio-oedema was expected to be lower than with omapatri-
lat.19–21 Given twice daily, sacubitril/valsartan leads to sustained
neprilysin and RAAS inhibition over a 24 h period addressing
one limitation of the OVERTURE trial in which omapatrilat
was given as a single large dose once daily.22 That approach may
have contributed to the significant early postdose hypotension
seen with omapatrilat but did not provide sustained inhibition
of ACE and neprilysin over 24 h. The systemic exposure deliv-
ered by sacubitril/valsartan 97 mg/103 mg (200 mg LCZ696) is
equivalent to 160 mg of valsartan and neprilysin is almost com-
pletely inhibited for up to 12 h.19–21
The Prospective comparison of ARNI with ACEI to
Determine Impact on Global Mortality and morbidity in Heart
Failure trial (PARADIGM-HF) was conducted to test whether
97 mg/103 mg twice daily of sacubitril/valsartan was superior to
enalapril 10 mg twice daily in reducing the primary end point
of CV death or HF hospitalisation.22–24 All randomised patients
completed a run-in period of 6–8 weeks during which it was
required that the target dose of both drugs was tolerated prior
to randomisation. Each treatment period (enalapril and sacubi-
tril/valsartan) included a washout period to avoid simultaneous
neprilysin and ACE inhibition and the potential risk of
angio-oedema (patients with a history of angio-oedema were
also excluded). The trial was terminated early, on the recom-
mendation of the Data Monitoring Committee, due to a sus-
tained and highly significant reduction in the risk of the primary
composite end point (CV death or HF hospitalisation) and in
CV mortality in the sacubitril/valsartan group compared with
the enalapril group. At the end of the trial, there was a 20%
relative risk reduction in the primary end point and each of its
components, as well as a 16% reduction in all-cause mortality.
The two major modes of CV death, sudden death and death
from worsening HF, were equally and significantly reduced.25
Both first hospitalisations for HF and total (including repeat)
hospitalisations were also reduced by 21% and 23%, respect-
ively (figure 2).26 Therefore, for every 1000 patients switched
Figure 1 Pathways blocked by ACE inhibitors, angiotensin receptor blockers and neprilysin inhibitors. ANP, atrial natriuretic peptide; BNP, B-type
natriuretic peptide; CNP, B-type natriuretic peptide.
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from enalapril to sacubitril/valsartan, over a median of
27 months, there would be: 47 less primary end points (CV
death or HF hospitalisations), 33 less CV deaths, 28 less first
hospitalisations for HF (53 less total hospitalisations for HF)
and 32 less deaths from any cause.24 No convincing or consist-
ent interaction between any of the subgroups and study out-
comes were observed.24 There was no statistically significant
difference in the rate of angio-oedema with sacubitril/valsartan
although numerically more cases were observed than in the ena-
lapril group (19 patients in the sacubitril/valsartan group and 10
cases in the enalapril group, p=0.13).24 Hypotension was sig-
nificantly more common with sacubitril/valsartan than with ena-
lapril (14% vs 9% in the in the sacubitril/valsartan and enalapril
groups respectively, p<0.001), although this rarely led to study-
drug discontinuation (0.9% and 0.7% in the sacubitril/valsartan
and enalapril groups respectively, p=0.38). Conversely, renal
dysfunction, hyperkalaemia and cough were less common with
sacubitril/valsartan than with enalapril. Subsequent analyses of
PARADIGM-HF have confirmed that the relative reductions in
morbidity and mortality and differential rates of adverse events
were similar across all ages27 (figure 3) and baseline risk of
death as determined by risk-scoring systems.28
ROBUSTNESS OF RESULTS OF PARADIGM-HF AND
REGULATORY APPROVAL
Regulatory approval of a new drug requires demonstration of
effectiveness and safety in either two trials with a two-sided
p<0.05 OR a single, large, internally consistent, multicentre
study with p<0.00125.29 PARADIGM-HF fulfils these criteria.
It was large (8399 patients randomised), highly statistically sig-
nificant (p=0.0000004), internally consistent (lack of subgroup
interactions), multicentre (sites were located in 47 countries),
and there were large effects on morbidity and mortality (CV
death or hospitalisation for HF was reduced by 20% and all-
cause mortality by 16%). If we ignore the argument that to
repeat the trial would be unethical, to achieve such a statistically
significant result on the primary end point would require four
Figure 2 Effect of sacubitril/valsartan on the rate of heart failure (HF)
hospitalisations as a time to first event analysis and as a recurrent
event analysis of total hospitalisations for.26
Figure 3 Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the
PARADIGM-HF trial according to age group.27 p for interaction for cardiovascular (CV) death or heart failure (HF) hospitalisation=0.94, for CV death
p for interaction=0.92, for HF hospitalisation p for interaction=0.81 and all-cause death p for interaction=0.99. PARADIGM-HF, Prospective
comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure.
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or five trials each with a p value of <0.05 to have the same
strength of evidence as provided by a single trial with a p
value=0.0000004 (table 1). Put another way, if sacubitril/valsar-
tan was in fact no better than enalapril the chances of observing
the treatment difference that was found in PARADIGM-HF is
less than one in a million.30 We believe that this finding creates
a unique question for the HF guideline committee. ‘Level A’ evi-
dence conventionally requires data from multiple randomised
trials or a well conducted meta-analysis (table 2). Usually, a soli-
tary randomised trial would confer a B level of evidence. Does
the robustness of the findings of PARADIGM-HF equate to two
trials or a meta-analysis?
WHO SHOULD BE PRESCRIBED SACUBITRIL/VALSARTAN?
The only evidence for the use of sacubitril/valsartan is in
patients with HF-REF. An outcomes trial of sacubitril/valsartan
versus valsartan in patients with HF and preserved ejection frac-
tion, the Prospective comparison of ARni with Arb Global
Outcomes in heart failure with preserved ejectioN fraction
(PARAGON-HF) is currently still recruiting (ClinicalTrials.gov
Identifier:NCT01920711). We also do not have robust data on
the use of this drug in hospitalised patients (although some data
are available31 a trial is underway ClinicalTrials.gov Identifier:
NCT02661217) or those with HF complicating an acute myo-
cardial infarction. Therefore, if we consider the inclusion and
exclusion criteria of the PARADIGM-HF trial, sacubitril/valsar-
tan can be given to: adult patients with HF, New York Heart
Association (NYHA) II–IV and a reduced ejection fraction
(≤40%) on a β-blocker and MRA as recommended by guide-
lines, with a systolic blood pressure of ≥100 mm Hg and esti-
mated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2
and potassium ≤5.2 mmol/L (figure 4). The US Food and Drug
Administration (FDA) and European Medicines Agency (EMA)
prescribing information is consistent with these groups.32 33
Although further inclusion criteria were stipulated in the trial
(patients had to have a BNP ≥150 pg/mL (NTpro-BNP
≥600 pg/mL) or if hospitalised with HF a BNP ≥100 pg/mL
(NTpro-BNP ≥400 pg/mL)) these are not part of the FDA or
EMA prescribing information, presumably because most patients
with HF-REF exceed these thresholds,34–36 there was no inter-
action between baseline natriuretic peptide concentration and
the effect of treatment24 and because there is no biological basis
for assuming sacubitril/valsartan would lose its effectiveness
below these thresholds. Supporting the prescribing information
from the FDA and EMA, cost-effectiveness analyses in private37
and public38 39 healthcare systems confirm that sacubitril/valsar-
tan is cost-effective.
WHEN SHOULD A PATIENT BE PRESCRIBED SACUBITRIL/
VALSARTAN?
Currently the prescribing information from FDA notes that
sacubitril/valsartan should be used in patients in place of an
ACE inhibitor or other ARB that is, that patients on these treat-
ments should be switched to ARNI.32 We are lacking evidence
for patients with newly diagnosed HF-REF. Should they be
established on an ACE inhibitor (or ARB) for at least 1 month
after which time they would have been eligible for
PARADIGM-HF that is, to switch to sacubitril/valsartan? The
FDA seems to have decided otherwise as their labelling also
gives recommendations on how to start sacubitril/valsartan in
ACE inhibitor/ARB-naïve patients (see below).32 This is prob-
ably logical (if not entirely evidence-based), as the lower risks of
renal dysfunction and hyperkalaemia with sacubitril/valsartan
may enable more patients to achieve optimal RAAS inhibition.
Furthermore, conducting a trial in ACE inhibitor/ARB-naïve
patients would be nearly impossible—recruitment would be
slow (given the much smaller number of patients with incident
heart failure) and cross-over from the ACE inhibitor group to
the sacubitril/valsartan group is likely to be very high, confound-
ing interpretation of outcomes. In the Safety and Tolerability of
Initiating LCZ696 in Heart Failure Patients (TITRATION)
study31 of dose escalation strategies of sacubitril/valsartan
(N=498) patients who were ACE inhibitor or ARB-naïve (7%)
and hospitalised (11%) were included. Rates of adverse events
were similar to those reported in PARADIGM-HF.
Furthermore, apart from these practical considerations, there
is no plausible scientific reason to believe the results of such a
trial would be different than PARADIGM-HF and an analysis of
the PARADIGM-HF trial by subgroup of duration of HF (those
with HF for ≤1 year, 1–5 years and >5 years) revealed no inter-
action between duration of HF and benefit from sacubitril/val-
sartan (p for interaction for the primary outcome=0.27).24
Table 1 Number of trials with a p value <0.05 to provide the
same level of evidence as PARADIGM-HF on the primary outcome
and cardiovascular death
Number of
trials with
p<0.05
showing
efficacy
p value required
by 1 trial to
provide the same
strength of
evidence
PARADIGM-HF p
value for primary
end point
PARADIGM-HF p
value for CV
death
1 trial 0.05
2 trials* 0.00125* 0.00008
(equivalent to 2–3
trials at p<0.05)
3 trials 0.00003125
4 trials 0.00000078 0.0000004
(equivalent to 4–5
trials at p<0.05)
5 trials 0.0000000195
Based on the formula (0.025)n×2 where n is the number of trials required (S Pocock
personal communication 2015).
*Usual regulatory requirement—2 trials at p<0.05 or 1 trial at p<0.00125.
Table 2 Class of recommendation and level of evidence
definitions used by major guideline bodies
Classes of
recommendations Definition
Class I Evidence and/or general agreement that a given
treatment or procedure is beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion
about the usefulness/efficacy of the given treatment
or procedure.
Class IIa Weight of evidence/opinion is in favour of
usefulness/efficacy.
Class IIb Usefulness/efficacy is less well established by
evidence/opinion.
Class III Evidence or general agreement that the given
treatment or procedure is not useful/effective, and in
some cases may be harmful.
Levels of evidence Definition
Level of evidence A Data derived from multiple randomised clinical trials
or meta-analyses.
Level of evidence B Data derived from a single randomised clinical trial
or large non-randomised studies.
Level of evidence C Consensus of opinion of the experts and/or small
studies, retrospective studies, registries.
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HOW SHOULD SACUBITRIL/VALSARTAN BE PRESCRIBED?
Sacubitril/valsartan should not be given in conjunction with
another ARB or renin inhibitor (because of the risk of renal
impairment and hyperkalaemia) or an ACE inhibitor (risk of renal
impairment, hyperkalaemia and angio-oedema). Due to the poten-
tial risk of angio-oedema when used concurrently with an ACE
inhibitor, sacubitril/valsartan must not be started for at least 36 h
after discontinuing an ACE inhibitor.32 Patients and carers should
discard any remaining doses to reduce the risk of accidental
dosing. The starting dose of sacubitril/valsartan is 49 mg/51 mg
twice daily. This should be reduced in certain groups (table 3). The
dose should be doubled every 2–4 weeks as tolerated by the
patient to the maximum dose of 97 mg/103 mg twice daily.
Patients should also be prescribed other evidence-based drugs
(β-blocker, mineralocorticoid receptor antagonist, ivabradine and
digoxin) and devices (cardiac resynchronisation therapy (CRT),
implantable cardioverter defibrillator (ICD)), as appropriate.
SIDE EFFECTS AND CAUTIONS
Renal function and potassium should be monitored as for any
other RAAS blocker. Similarly blood pressure should also be mon-
itored and we would suggest that the drug is not started in those
with a systolic blood pressure of <100 mmHg in keeping with
the exclusion criteria of the trial. In the event of the development
of hypotension, renal impairment or hyperkalaemia, evaluation of
the potential causes should be sought and appropriate changes
made. For example, reducing the dose of other non-essential
blood pressure-lowering drugs, adjusting the dose of diuretics, dis-
continuing other drugs such as non-steroidal anti-inflammatory
drugs. Of course dose reduction or discontinuation of sacubitril/
valsartan should also be considered in these scenarios after assess-
ment of the patient. The development of angio-oedema should
lead to immediate discontinuation and treatment with appropriate
therapy until it has resolved. Permanent treatment discontinuation
was not common in the PARADIGM-HF trial with rates of dis-
continuation similar in the sacubitril/valsartan group and the ena-
lapril group for hypotension and hyperkalaemia (all <1%).24
Rates of discontinuation for renal impairment were lower in the
sacubitril/valsartan group compared with the enalapril group
(0.7% vs 1.4% respectively, p=0.002).
One final issue worthy of note is that of treatment monitor-
ing. Monitoring the treatment and prognosis of patients with
HF by tracking natriuretic peptides is still an area of great inter-
est.40 Sacubitril/valsartan increases levels of circulating BNP
therefore BNP is not useful for monitoring the prognosis of
these patients.26 NT-proBNP is still useful as changes in the
levels of this inactive peptide continue to reflect reduced
pre-proBNP secretion as a result of reduction in wall stress.26
Neprilysin has a higher affinity for other natriuretic peptides
such as ANP and CNP than it does for BNP. Therefore, other
natriuretic peptides may be more useful to monitor treatment
response and the level of neprilysin inhibition, although
whether this would predict prognosis is unclear.
HEART FAILURE WITH PRESERVED EJECTION FRACTION
There is also experience with sacubitril/valsartan in heart failure
with preserved ejection fraction (HF-PEF). In the Prospective
comparison of ARNI with ARB on Management Of heart failUre
with preserved ejectioN fracTion (PARAMOUNT) trial, 301
patients with HF-PEF were randomised to valsartan or sacubitril/
valsartan.41 NT-proBNP fell in the latter group along with reduc-
tions in NYHA class and left atrial volumes. On the basis of these
findings and the favourable effects seen in PARADIGM-HF a
large multicentre randomised outcomes trial of sacubitril/valsar-
tan versus valsartan, PARAGON-HF, is currently recruiting.
SUMMARY
Even in patients with HF-REF with mild symptoms, apparently
‘stable’ on conventional treatment, it is clear that morbidity and
Figure 4 Stepwise treatment of patients with symptomatic (NYHA II–
IV) heart failure with reduced ejection fraction. Progressive therapies
should be added in a stepwise fashion. Where two or more options
exist on a step the most appropriate therapy for the patient based on
concomitant medication or the presence of other patient factors should
be made. NYHA, New York Heart Association; ARB, angiotensin
receptor blocker; ACE, angiotensin converting enzyme inhibitor; ICD,
implantable cardioverter defibrillator; CRT-P, cardiac resynchronisation
therapy-pacemaker; CRT-D, cardiac resynchronisation therapy-
defibrillator; LVAD, left ventricular assist device.
Table 3 Starting dose and dose titration for sacubitril/valsartan in a variety of patient populations with heart failure and reduced ejection
fraction (HF-REF)
Population with HF-REF
Starting dose of sacubitril/
valsartan Uptitration and target dose
No patient characteristics requiring caution or dose reduction 49 mg/51 mg twice daily Uptitration by doubling of dose every 2–4 weeks until a
target dose of 97 mg/103 mg twice daily is reached.Currently only taking a low or just low target dose of ACE inhibitor or
ARB†
24 mg/26 mg twice daily
No ACE inhibitor or ARB in the past 24 mg/26 mg twice daily
eGFR <30 mL/min/m2‡ 24 mg/26 mg twice daily
Moderate hepatic impairment (Child–Pugh class B) 24 mg/26 mg twice daily
Elderly 24 mg/26 mg twice daily
†Target doses of ACE inhibitors and ARBs are as follows: ACE inhibitors—captopril 50 mg three times a day, enalapril 10 mg twice daily, lisinopril 20 mg once a day, ramipril 5 mg
twice daily, trandolopril 4 mg once a day ARBs—candesartan 32 mg once a day, losartan 150 mg once a day, valsartan 160 mg once a day.
‡The European Medicines Agency also suggests that a dose of 24 mg/26 mg can be considered if eGFR is 30–60 mL/min/m2.33
ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.
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mortality remains high and that substitution of sacubitril/valsartan
for an ACE inhibitor leads to rapid and substantial improvement in
outcomes. Therefore, it is our view that an ARNI should replace an
ACE inhibitor (or an ARB) as a foundation of treatment for
HF-REF and already this view is reflected in new guidelines.42 43
The results of the PARAGON-HF trial will determine whether
sacubitril/valsartan has any place in the management of HF-PEF.
The speed of adoption of sacubitril/valsartan will depend on a
number of different factors, including cost-effectiveness.
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